Contribution to FDI
Healthcare and pharmaceuticals are an emerging yet increasingly significant component of ASEAN’s FDI landscape, contributing through manufacturing, services, and integrated value chain activities. Although still relatively small compared to major sectors, health care FDI has grown steadily, with greenfield investment projects rising by more than 40 per cent, from an annual average of about $1.4 billion in 2009–2013 to $2 billion in 2014–2018. The sector is strongly supported by the presence of multinational enterprises, with 79 of the world’s 100 largest pharmaceutical companies operating in ASEAN across multiple Member States and business functions.
These investments span pharmaceutical production, distribution, regional headquarters, and research-related activities. Healthcare services also contribute significantly, particularly through expanding private hospital networks and supporting industries such as health insurance, medical devices, and logistics. The sector’s contribution is further reinforced by rising healthcare demand, with total expenditure estimated at $99 billion in 2016 and projected to reach around $270 billion by 2025. While FDI volumes remain smaller relative to manufacturing or finance, healthcare and pharmaceuticals are strategically important due to their role in supporting human capital, improving productivity, and enabling long-term economic resilience.
Current Trend
The current trend in ASEAN’s healthcare and pharmaceutical sectors shows strong growth in investment, increasing diversification, and deeper integration across the value chain. Pharmaceutical investment is expanding across multiple ASEAN Member States, with multinational enterprises establishing manufacturing facilities, research centres, and regional headquarters. Countries such as Singapore have emerged as key hubs for high-value pharmaceutical investment, while others are attracting production and distribution activities. The sector is supported by a strong base of global firms, with most major pharmaceutical MNEs operating subsidiaries in three or more ASEAN countries.
Investment activity is also expanding beyond pharmaceuticals into healthcare services, medical devices, and digital health solutions. Venture capital and private equity are playing a growing role, with healthcare among the most targeted sectors for investment. At the same time, healthcare start-ups—particularly in telemedicine, medical technology, and digital platforms—are scaling rapidly, supported by increasing funding. Medical tourism is another key trend, with ASEAN countries attracting significant patient inflows, further stimulating private investment in hospitals and related services. Overall, the sector is evolving toward a more integrated ecosystem that combines manufacturing, services, and innovation, driven by both domestic demand and international investment strategies.
Driving Factor
FDI into healthcare and pharmaceuticals in ASEAN is driven primarily by strong and expanding demand, supported by demographic and structural factors. Population growth, urbanisation, and rising income levels are increasing demand for healthcare services and pharmaceutical products across the region. ASEAN’s healthcare expenditure remains relatively low at about 4 per cent of GDP, compared to the global average of around 10 per cent, indicating significant growth potential. At the same time, the region’s population is projected to exceed 700 million in the coming years, with a rapidly expanding middle class and increasing life expectancy, further intensifying demand for healthcare services.
Rising incidence of non-communicable diseases is also driving demand for more advanced treatment and pharmaceutical products. Governments play a key role by promoting investment through policy frameworks, regulatory reforms, and incentives, as well as expanding universal healthcare coverage in several countries. Multinational enterprises are also investing to strengthen supply chain resilience and regional distribution networks. In addition, the liberalisation of foreign equity ownership in healthcare in many ASEAN countries has facilitated greater foreign participation in the sector. These combined factors create strong investment opportunities, positioning healthcare and pharmaceuticals as a high-growth sector for FDI in ASEAN.
Outlook
The outlook for healthcare and pharmaceutical FDI in ASEAN is highly positive, supported by sustained demand growth and expanding investment opportunities across the value chain. Healthcare expenditure is expected to increase significantly, reaching approximately $270 billion by 2025, reflecting rising income levels, demographic changes, and expanding healthcare access. The sector is likely to attract continued investment from multinational enterprises, particularly in pharmaceutical manufacturing, medical devices, and high-value services. ASEAN’s role as a regional hub for pharmaceutical operations is expected to strengthen further, supported by the presence of global industry leaders and increasing integration across Member States.
Digital health technologies, including telemedicine, artificial intelligence, and data-driven healthcare solutions, are also expected to become an important area of future investment. However, several challenges remain, including regulatory fragmentation, skills shortages, and uneven infrastructure development across countries. Addressing these constraints will be essential to sustain long-term growth and attract higher-value investment. Despite these challenges, the region’s strong fundamentals—including a large and growing population, rising healthcare demand, and improving investment environment—provide a solid foundation. Healthcare and pharmaceuticals are therefore expected to play an increasingly important role in ASEAN’s FDI landscape and broader economic development.
